Obstructive Sleep Apnea Market is Flourishing with the Innovation of Newer Treatment Devices

Obstructive sleep apnea is a sleeping disorder where the breathing gets interrupted sporadically during sleep. This disorder occurs when the throat muscles shrink and block the air way when the person is asleep. of obstructive sleep apnea. Patients with neurological disorder are more prone to sleep apnea.

Snoring being the most noticeable sign of the disorder, excessive daytime sleepiness, non-refreshing sleep, chocking, and snoring, are the most common symptoms of the obstructive sleep apnea. It is being predicted that 9-26% of middle aged population are experiencing obstructive sleep apnea more than 15 times in an hour.

Market Growth Drivers

Rising cases of undiagnosed patient and rising awareness in the therapeutic obstructive sleep apnea is anticipated to boost the growth of therapeutic obstructive sleep apnea device market.

It has been predicted that approximately 80% of people who are facing obstructive sleep apnea are undiagnosed. If obstructive sleep apnea is left untreated, it may further cause various health issues such as diabetes, high blood pressure and sometimes it may even cause death. 

The rising sleep apnea cases is the key factor for the growth of therapeutic obstructive sleep apnea 

The growing cases of sleep apnea and the treatment followed by patient is very less, so spreading awareness among the patient about the sleep apnea devices can be considered as one of the main driving factor for therapeutic obstructive sleep apnea devices.

Obstacles

The biggest restraint in the therapeutic obstructive sleep apnea device market is that the patients are not tolerating the device. The device consists of a mask which causes discomfort to the patient as the pipe is attached to the mask and the mask is being completely covered which make the patient claustrophobic. 

The high cost of the sleep apnea devices can be considered as one of the biggest restraint for the growth of the therapeutic obstructive sleep apnea devices. Due to fear and high cost, customers lose interest in these devices which is anticipated to hamper the growth of therapeutic obstructive sleep apnea device market.

Recent Developments

Positive airway pressure therapy can treat sleep apnea. However, this treatment isn’t convenient for each and every patient. After many experiments, there are now many new and advanced devices have been introduced for better treatment of the disorder.

Hypoglossus Nerve Stimulation

Hypoglossus nerve stimulation (HNS) is a completely different approach for OSA treatment. This approach was approved by FDA in 2014. With HNS, a small device is surgically implanted in the chest. The device can be turned on and off by the patient which makes it more convenient. While you sleep, the device monitors your breathing and stimulates a nerve that keeps the upper airway open.

Expiratory Positive Airway Pressure (EPAP)

In the EPAP system, the disposable adhesive valves are placed over the nose when the patient is asleep. While inhaling, the valve opens and helps the airway remain clear. In time of exhaling, the airflow is directed into small channels, which creates pressure and keeps the airways free.

Leading companies operating in the therapeutic obstructive sleep apnea devices are BMC Medical Co., Ltd, Becton Dickinson (CareFusion Corporation). Braebon Medical Corporation, Cadwell Laboratories Inc., Compumedics Limited, Curative Medical Inc., Fisher & Paykel Healthcare, GE Healthcare, ImThera Medical, Inc., Invacare Corporation, and many more. 

According to a recent report by Research Dive, the global therapeutic obstructive sleep apnea device market forecasted to grow at a CAGR of 9.6% generating a revenue of $9,561.3 million by 2026 from $4661.6 million in 2018.